 Silence Therapeutics PLC LON:SLN, NASDAQ:SLN said it has received the final US40mln from a US80mln cash and equity investment from AstraZeneca, adding that it expects to be working on up to five targets in the next three years with the Anglo-Swedish giant. The collaboration, which was inked last March, provides AZ scientists with access to Silences small interfering RNA, or siRNA technology, and specifically the mRNAi GOLD platform. 